Apnimed, Inc. risk profile
45 Elevated one input has moved against it
Measured 21 October 2026 from APMD's filed statements. Recomputed nightly.
45 (Elevated), driven by Competitive position at 69, over 4 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 63 | Stretched | Worsening | Drawdown from the 52-week high — 49.0% |
| Operating pressure | 0 | Contained | Stable | Costs outgrowing revenue — -404.6 percentage points |
| Cash conversion | Reads operating_cashflow, capital_expenditure, free_cashflow, net_income and revenue. No reading is stored for this company. | |||
| Leverage and coverage | 31 | Normal | Worsening | Current ratio — 0.41x |
| Competitive position | 69 | Stretched | Stable | Operating-margin gap against peers — -140.5 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.